X4 PHARMACEUTICALS, INC Marketable Securities, Unrealized Gain (Loss)
X4 PHARMACEUTICALS, INC (XFOR) reported Marketable Securities, Unrealized Gain (Loss) of -$1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$1.00K.
- X4 PHARMACEUTICALS, INC marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$13.00K.
- X4 PHARMACEUTICALS, INC marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $20.00K, a 55.56% decline year-over-year.
- X4 PHARMACEUTICALS, INC marketable securities, unrealized gain (loss) for the quarter ending 2025-06-30 was -$10.00K.
- X4 PHARMACEUTICALS, INC marketable securities, unrealized gain (loss) for fiscal 2025 was $13.00K.
- X4 PHARMACEUTICALS, INC marketable securities, unrealized gain (loss) for fiscal 2024 was -$3.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K 10-Q · filed 2026-08-06 | -$14.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$13.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $13.00K 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $20.00K 10-Q · filed 2025-11-05 | $10.00K derived: sum of 2 quarters · filed 2026-08-06 | $4.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$10.00K 10-Q · filed 2026-08-06 | -$16.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$6.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | -$3.00K 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $45.00K 10-Q · filed 2025-11-05 | $41.00K derived: sum of 2 quarters · filed 2025-11-05 | $5.00K derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$4.00K 10-Q · filed 2025-11-05 | -$40.00K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | -$36.00K 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |